4
Changes in Ownership
Dyne Therapeutics, Inc. Filed Acc 0000950170-24-024300
CEO & President sold 100,000 shares at an average $28.96 ($2,895,519)
- CEO & President acquired 100,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Brumm Joshua T CEO & President | 2024-02-29 | Option exercise 10b5-1 | +5,520 | $5.54 | $30,581 | 568,991 | D |
| Brumm Joshua T CEO & President | 2024-02-29 | Sale 10b5-1 | −5,520 | $27.50 | $151,800 | 563,471 | D |
| Brumm Joshua T CEO & President | 2024-03-01 | Option exercise 10b5-1 | +94,480 | $5.54 | $523,419 | 657,951 | D |
| Brumm Joshua T CEO & President | 2024-03-01 | Sale 10b5-1 | −18,976 | $28.25 | $536,072 | 638,975 | D |
| Brumm Joshua T CEO & President | 2024-03-01 | Sale 10b5-1 | −74,090 | $29.23 | $2,165,651 | 564,885 | D |
| Brumm Joshua T CEO & President | 2024-03-01 | Sale 10b5-1 | −1,414 | $29.70 | $41,996 | 563,471 | D |
| Derivatives | |||||||
| Brumm Joshua T CEO & President | 2024-02-29 | Option exercise · Stock option (right to buy) 10b5-1 | −5,520 | 102,343 | D | ||
| Brumm Joshua T CEO & President | 2024-03-01 | Option exercise · Stock option (right to buy) 10b5-1 | −57,843 | 44,500 | D | ||
| Brumm Joshua T CEO & President | 2024-03-01 | Option exercise · Stock option (right to buy) 10b5-1 | −36,637 | 342,681 | D | ||
| Open-market sales · 100,000 sh · avg $28.96 · $2,895,519 | |||||||
Loading xslF345X05/ownership.xml…